| Stereochemistry | RACEMIC |
| Molecular Formula | C22H23N3O2.ClH |
| Molecular Weight | 397.898 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)C1=C2C3CN(C)CCN3C4=C(CN2C5=C1C=CC=C5)C=CC=C4
InChI
InChIKey=YEITZTKANLXOTH-UHFFFAOYSA-N
InChI=1S/C22H23N3O2.ClH/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23;/h3-10,19H,11-14H2,1-2H3;1H
| Molecular Formula | C22H23N3O2 |
| Molecular Weight | 361.4369 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Serazapine (CGS15040) is an anxiolytic agent. It is structurally novel 5-HT2 receptor antagonist. Preliminary preclinical findings indicated an anticonflict effect in a behavioral suppression test, and two preliminary investigations in volunteers also suggested anxiolytic potential. In the first of these studies serazapine resembled diazepam, a reference anxiolytic drug, electroencephalographically. Additionally, in a test of psychogenic stress in volunteers it reduced cardiac output.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
A double-blind, randomized, placebo-controlled
four-compartment parallel group, multicenter trial in outpatients with Generalized Anxiety Disorder (GAD): a 14-to 30-day drug-free interval preceded study entry. For all qualified patients, a 1-week, single-blind placebo washout period was followed by a 5-week, double-blind treatment phase involving a once daily oral dose of either 10 mg, 20 mg, or 40 mg of Serazapine (CGS15040), or placebo. The 40-mg group tended to perform
better (larger decreases from baseline in the total Ham-A
score) than the other groups.
Route of Administration:
Oral
